Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Sponsor: AstraZeneca
A PHASE1 clinical study on Advanced (Inoperable) Non Small Cell Lung Cancer and Advanced Non Small Cell Lung Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 34 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
34 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 29 earlier versions
-
Jul 2023 — Apr 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Mar 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Dec 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE1
-
Jul 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE1
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Aug 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1
-
Jul 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .